LCAP vs. PGNY, SDGR, ENOV, ARDT, LMAT, INDV, PINC, BHC, FOLD, and GLPG
Should you be buying Lionheart Acquisition Co. II stock or one of its competitors? The main competitors of Lionheart Acquisition Co. II include Progyny (PGNY), Schrödinger (SDGR), Enovis (ENOV), Ardent Health Partners (ARDT), LeMaitre Vascular (LMAT), Indivior (INDV), Premier (PINC), Bausch Health Companies (BHC), Amicus Therapeutics (FOLD), and Galapagos (GLPG). These companies are all part of the "medical" sector.
Lionheart Acquisition Co. II vs. Its Competitors
Progyny (NASDAQ:PGNY) and Lionheart Acquisition Co. II (NASDAQ:LCAP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, community ranking, earnings and risk.
Progyny received 102 more outperform votes than Lionheart Acquisition Co. II when rated by MarketBeat users.
Progyny has a net margin of 5.03% compared to Lionheart Acquisition Co. II's net margin of 0.00%. Progyny's return on equity of 11.36% beat Lionheart Acquisition Co. II's return on equity.
94.9% of Progyny shares are held by institutional investors. 9.4% of Progyny shares are held by company insiders. Comparatively, 19.4% of Lionheart Acquisition Co. II shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Progyny presently has a consensus price target of $23.45, indicating a potential upside of 11.50%. Given Progyny's stronger consensus rating and higher possible upside, equities analysts clearly believe Progyny is more favorable than Lionheart Acquisition Co. II.
In the previous week, Progyny had 10 more articles in the media than Lionheart Acquisition Co. II. MarketBeat recorded 10 mentions for Progyny and 0 mentions for Lionheart Acquisition Co. II. Progyny's average media sentiment score of 0.68 beat Lionheart Acquisition Co. II's score of 0.00 indicating that Progyny is being referred to more favorably in the media.
Progyny has higher revenue and earnings than Lionheart Acquisition Co. II.
Progyny has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Lionheart Acquisition Co. II has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500.
Summary
Progyny beats Lionheart Acquisition Co. II on 13 of the 14 factors compared between the two stocks.
Get Lionheart Acquisition Co. II News Delivered to You Automatically
Sign up to receive the latest news and ratings for LCAP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LCAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lionheart Acquisition Co. II Competitors List
Related Companies and Tools
This page (NASDAQ:LCAP) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy LCAP Stock Free LCAP Stock Alerts